


- Development in accordance of ADAPTE method and additional literature review
- 22 working group members
- External rewieiving by a multidisciplinary panel of 27 reviewers
- Recommandations developed using the GRADE methodology

Methodes

	METHOTREXATE	ACITRETINE	CICLOSPORINE	APREMILAST	DEUCRAVACITINIB	INFLIXIMAB	ADALIMUMAB	ETANERCEPT	CERTOLIZUMAB	USTEKINUMAB	IXEKIZUMAB	SECUKINUMAB	BRODALUMAB	BIMEKIZUMAB	GUSELKUMAB	RISANKIZUMAB	TILDRAKIZUMAB	SPESOLIMAB
Nail involvement	↑ Expert opinion	0	0	↓	0	↑	↑	↑	↑	↑ Expert opinion	↑*	↑*	↑*	↑*	↑	↑	↑	
Palmoplantar pustular psoriasis	0	↑	↑*	0	0	0	0	0	0	↓	↑*	↑*	↑*	↑*	↑*	↑*	↑*	↓
High risk of atherosclerotic cardiovascular disease	↑↑	↓↓	↓↓		0	↑↑	↑↑	↑↑	↑↑	↓	↑ Expert opinion	↑ Expert opinion	↑ Expert opinion	↑ Expert opinion	0	0	0	
Diabetes			↓↓															
Inflammatory bowel disease	↑		↑	↑	0	↑↑	↑↑	↓	↑↑	↑↑	↓↓	↓↓	↓↓	↓↓	↑↑*	↑↑*	↑↑	
History of cancer < 5 years or active cancer (except NMSC)	↑↑	↑↑	↓↓	↑	↓↓Expert opinion	↑	↑*	↑*	↑*	↑*	↑	↑	↑	↑	↑	↑	↑	
Short term pregnancy wish and Pregnancy	↓↓	↓↓	↑	↓↓	↓↓	↑	↑	↑	↑↑	↑	0	↑	0	0	0	0	0	

Special patient populations



Decision-making algorithm

* when rapid efficacy and short-term disease control is needed in case of recent outbreak of psoriasis or severe flare up, ** preferred biosimilars if the price is lower
TNFi : TNF inhibitors ; IL-12/23i : IL-12/23 inhibitors ; IL-17i: IL-17 inhibitors ; IL-23i : IL-23 inhibitors ; PDE4i : phophodiesterase-4 inhibitors ; TYK : Tyrosine kinase